<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03923049</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300002877</org_study_id>
    <nct_id>NCT03923049</nct_id>
  </id_info>
  <brief_title>Feasibility and Accuracy of Hybrid Magnetic Resonance and Positron Emission Tomography With 18F-Fluorodeoxyglucose in Diagnosing Cardiac Sarcoidosis</brief_title>
  <official_title>Feasibility and Accuracy of Hybrid Magnetic Resonance and Positron Emission Tomography With 18F-Fluorodeoxyglucose in Diagnosing Cardiac Sarcoidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose and objectives of the study is to establish the feasibility of the simultaneous
      PET/MR in patients with cardiac sarcoidosis, determine relationships between various imaging
      biomarkers like extracellular volume (ECV) and standardized uptake values (SUV) from FDG-PET
      and to evaluate the diagnostic accuracy of the simultaneous method in comparison to the
      PET/CT and cardiac MRI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who meet the inclusion criteria and agree to the study will be recruited from the
      Kirklin Clinic and UAB hospitals who will be undergoing FDG-PET/CT for cardiac study as part
      of their standard of care to diagnose cardiac sarcoidosis. MRI and FDG-PET screening
      questionnaire will be completed. A chart review will be completed to obtain data from patient
      medical records pertaining to study including age, gender, race, weight, height, vital signs,
      social and family history, past medical history especially if there is any history of
      hypertension, diabetes, high cholesterol levels, heart failure or history of lung diseases,
      lab results including brain natriuretic peptide levels, creatinine, hemoglobin, coagulation
      parameters, results of stress test/left heart catheterization, prior echocardiography if
      available. The CMR will be done solely for research purposes. The patient will be in the
      PET/MRI scanner for cardiac study only for 60-90 minutes, Finally, multi-sequence,
      multi-planar cardiac MR images will be acquired to assess cardiac chamber size, regional wall
      motion abnormalities, ejection fraction, left ventricular perfusion(using gadolinium-based
      agent) and late gadolinium enhancement.

      The investigators will also conduct MRI examinations on 5 healthy volunteers to establish
      cardiac MRI protocol for the PET/MRI scanner. These scans will not involve any FDG
      administration to the healthy volunteers. These will involve cardiac MRI examinations to
      determine the feasibility and quality of MRI scans with the new scanner.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>diagnosing cardiac sarcoidosis using combined 18F-FDG-PET/MRI examination</measure>
    <time_frame>baseline through 24 hours</time_frame>
    <description>diagnostic accuracy of FDG-PET/MRI test will be determined by comparing the PET/MRI test against the Heart Rhythm Society (HRS) criteria which is the standard of reference.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cardiac Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>PET/MRI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Diagnostic testing with simultaneous PET/MRI for cardiac sarcoidosis diagnosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>hybrid PET/MRI</intervention_name>
    <description>On the day of the procedure, subjects will undergo a PET scan followed by MRI scan.</description>
    <arm_group_label>PET/MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Subjects older than 18 years of age with high suspicion of cardiac sarcoidosis and/or
        biopsy proven extracardiac sarcoidosis and/or positive HRS criteria will be enrolled.

        Exclusion Criteria:

          1. Coronary artery disease

          2. Insulin dependent diabetes

          3. Claustrophobia

          4. Pregnancy/nursing

          5. Presence of pacemaker or automatic implantable cardioverter-defibrillator

          6. Impaired renal function (estimated glomerular filtration rate &lt;45 ml/min/1.73 m2) will
             be excluded.

          7. Inability to undergo PET/MRI due to any other condition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sudeep Aryal, MD</last_name>
    <phone>205-975-9859</phone>
    <email>saryal@uabmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sudeep Aryal, MD</last_name>
      <phone>205-934-0820</phone>
      <email>saryal@uabmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2019</study_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Navkaranbir Bajaj</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 21, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT03923049/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

